Literature DB >> 2547901

Selective inhibition of nerve growth factor-stimulated protein kinases by K-252a and 5'-S-methyladenosine in PC12 cells.

D S Smith1, C S King, E Pearson, C K Gittinger, G E Landreth.   

Abstract

K-252a, a protein kinase inhibitor isolated from the culture broth of Nocardiopsis sp., inhibits the nerve growth factor (NGF)-stimulated phosphorylation of microtubule-associated protein 2 (MAP2) and Kemptide (synthetic Leu-Arg-Arg-Ala-Ser-Leu-Gly) by blocking the activation of two independent kinases in PC12 cells: MAP2/pp250 kinase and Kemptide kinase. The NGF-stimulated activation of these kinases is inhibited in a dose-dependent manner following treatment of the cells with K-252a. Although these kinases also are activated by epidermal growth factor (EGF) and 12-O-tetradecanoyl-phorbol 13-acetate, K-252a has no inhibitory effect when these agents are used. Half-maximal inhibition of the activation of both kinases was observed at 10-30 nM K-252a. K-252a was shown to directly inhibit the activity of MAP2/pp250 kinase and Kemptide kinase when added to the phosphorylation reaction mixture in vitro; however, half-maximal inhibition under these conditions was observed at greater than or equal to 50 nM K-252a. These data suggest that K-252a exerts its effects at a step early in the cascade of events following NGF binding. The effects of K-252a are similar to those reported for 5'-S-methyladenosine (MTA) and other methyltransferase inhibitors. Treatment of PC12 cells with MTA inhibited NGF-, but not EGF-mediated activation of MAP2/pp250-kinase (Ki greater than 500 microM). MTA, when added to the phosphorylation reaction mixture in vitro, directly inhibited kinase activity (Ki = 50 microM), suggesting that the effects of MTA may be the result of its action on protein kinases rather than methyltransferases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547901     DOI: 10.1111/j.1471-4159.1989.tb11776.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Lipopolysaccharide-induced NF-kappa B activation in mouse 70Z/3 pre-B lymphocytes is inhibited by mevinolin and 5'-methylthioadenosine: roles of protein isoprenylation and carboxyl methylation reactions.

Authors:  R E Law; J B Stimmel; M A Damore; C Carter; S Clarke; R Wall
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

2.  Tyrosine kinase activity coupled to the high-affinity nerve growth factor-receptor complex.

Authors:  S O Meakin; E M Shooter
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

Review 3.  Extracellular signal-regulated kinases: ERKs in progress.

Authors:  M H Cobb; T G Boulton; D J Robbins
Journal:  Cell Regul       Date:  1991-12

4.  AAK1 identified as an inhibitor of neuregulin-1/ErbB4-dependent neurotrophic factor signaling using integrative chemical genomics and proteomics.

Authors:  Letian Kuai; Shao-En Ong; Jon M Madison; Xiang Wang; Jeremy R Duvall; Timothy A Lewis; Catherine J Luce; Sean D Conner; David A Pearlman; John L Wood; Stuart L Schreiber; Steven A Carr; Edward M Scolnick; Stephen J Haggarty
Journal:  Chem Biol       Date:  2011-07-29

5.  EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.

Authors:  Ayse Batova; Howard Cottam; John Yu; Mitchell B Diccianni; Carlos J Carrera; Alice L Yu
Journal:  Blood       Date:  2005-10-18       Impact factor: 22.113

6.  Activation of mitogen-activated protein kinase by heat shock treatment in Drosophila.

Authors:  F Chen; M Torres; R F Duncan
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

7.  Identification of a nerve growth factor- and epidermal growth factor-regulated protein kinase that phosphorylates the protooncogene product c-Fos.

Authors:  L K Taylor; D R Marshak; G E Landreth
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.